Allergan agrees potential US$362m licensing deal with Medytox

Published: 27-Sep-2013
Research & Development

To develop neurotoxin products including a liquid-injectable treatment


US-based specialist pharmaceutical firm Allergan has entered into a licensing agreement with biopharmaceutical firm Medytox of Korea to develop certain neurotoxin product candidates currently in development.

The deal includes a potential liquid-injectable product.

Allergan will pay Medytox US$65m up front, in addition to a possible $116.5m in development milestones plus another $180.5m in sales milestones.

Under the agreement, Medytox will grant Allergan exclusive rights, worldwide outside Korea, to the new drugs.

The transaction closure is dependent on obtaining certain government approvals.

  • Companies:
  • Allergan
  • Medy Tox Inc
See more

You may also like

Ingredients

Therapeutic: atogepant for migraine

Read more
Migraine is thought to affect more than a billion people around the world and can have a significant impact on quality of life

Trending Articles

  1. Naobios and Sumagen sign exclusive partnership to develop HIV vaccine Naobios will manage process development and initiate launch of cGMP manufacturing for phase II clinical trials
  2. 4SC AG receives Paediatric Investigation Plan waiver for resminostat from the UK MHRA The waiver allows the company to avoid investigating the CTCL drug in a paediatric population, as it's considered unnecessary or inappropriate for use by this patient group
  3. Rapid increase in purchasing teams expected at CPHI North America Macro-uncertainty and large CDMO acquisitions attributed to have driven a surge in R&D, purchasing and QC/QA attendees at event
  4. Cresset creates new Vice President role to lead its AI strategy Dr Mutlu Dogruel joins from Microsoft, where he was responsible for empowering organisations to implement scalable AI solutions into their workflow
  5. Scleroderma treatment by Certa Therapeutics granted US FDA fast track FT011 is a novel, first-in-class oral therapy for the treatment of chronic fibrosis in multiple organs

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Ingredients

Therapeutic: atogepant for migraine

Migraine is thought to affect more than a billion people around the world and can have a significant impact on quality of life
Recruitment

CGT Catapult addresses skills gap with apprenticeship programme for advanced therapies

Programme will address the projected skills shortage facing public and private employers in the growing cell and gene therapy sector
Research & Development

Allergan acquires Topokine Therapeutics to focus on non-invasive fat reduction programme

Acquisition adds to Allergan's robust mid-to-late stage pipeline and reinforces its leadership in aesthetics innovation
Research & Development

Allergan and Heptares enter global R&D licensing agreement potentially worth US$3.35bn

For the development of treatments for Alzheimer’s and other neurological disorders
Regulatory

Antidepressant – rapastinel

Amost half of all patients with major depression are inadequately treated by common antidepressants, so alternatives are very much required
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Fostering the development of innovative medicines

Confidence in the pharma sector seems to be picking up, with higher drug approvals in the US, M&A activity increasing and opportunities in emerging markets. However, healthcare reforms and pricing pressures are driving the industry to improve productivity and gain a better knowledge of disease mechanisms at the molecular level. Data sharing and collaborative projects seem to be the way forward
Research & Development

Allergan and Molecular Partners to develop ophthalmic products

Sign two agreements to develop DARPin products to treat eye diseases
Subscribe now